Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Oxaliplatin

🥰Excellent
Catalog No. T0164Cas No. 61825-94-3
Alias L-OHP

Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.

Oxaliplatin

Oxaliplatin

🥰Excellent
Purity: 99.93%
Catalog No. T0164Alias L-OHPCas No. 61825-94-3
Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.
Pack SizePriceAvailabilityQuantity
5 mg$30 In Stock
25 mg$40 In Stock
50 mg$50 In Stock
100 mg$68 In Stock
200 mg$117 In Stock
500 mg$139 In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Oxaliplatin"

Select Batch
Purity:99.93%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.
Targets&IC50
U-373MG cells:2.95 μM, RT4 cells:11 μM, HT29 cells:0.33 μg/mL, WiDr cells:0.13 μg/mL, HT-29 cells:0.97 μM, TCCSUP cells:15 μM, HT-144 cells:7.85 μM, LS174T cells:0.19 μg/mL, SK-MEL-2 cells:30.9 μM, A2780 cells:0.17 μM, SW620 cells:1.13 μg/mL, U-87MG cells:17.6 μM
In vitro
METHODS: Human colon cancer cells HT29, SW620, WiDr and LS174T were treated with Oxaliplatin (0.001 ng/ml-100 µg/mL) for 24 h, and cytotoxicity was detected using MTT method.
RESULTS: Oxaliplatin was cytotoxic to HT29, SW620, WiDr and LS174T cells, with IC50s of 0.33, 1.13, 0.13 and 0.19 μg/mL, respectively.[1]
METHODS: Human colon cancer cells HCT116 WT and CHK2 KO were treated with Oxaliplatin (40 µM) for 24-96 h. Apoptosis was detected by Flow Cytometry.
RESULTS: Oxaliplatin treatment for 24-96 h increased apoptosis levels in WT and CHK2-KO cell lines. From 24-72 h, the apoptosis level of WT cells was consistently twofold lower than that of CHK2 KO cells. However, treatment for 96 h resulted in the same level of apoptosis in WT and CHK2-KO cells (85%). [2]
METHODS: Human oral squamous cell carcinoma cells CAL27 and SCC25 were treated with Oxaliplatin (31.25-125 μM) and Oxaliplatin (25-100 μM) for 12-36 h. Cell migration was detected using the Wound-healing method.
RESULTS: Oxaliplatin inhibited the migration of CAL27 and SCC25 cells in a dose-dependent manner. [3]
In vivo
METHODS: To detect anti-tumor activity in vivo, Oxaliplatin (5 mg/kg) and piperlongumine (2.5 mg/kg) were administered intraperitoneally once a day for twenty-four days to BALB/c nu/nu mice bearing human colorectal carcinoma tumor HCT-116.
RESULTS: The combination of Oxaliplatin and piperlongumine significantly inhibited tumor growth, and piperlongumine sensitized tumors to Oxaliplatin through ROS-mediated apoptosis in vivo. [4]
METHODS: To model platinum-induced painful peripheral neuropathy, Oxaliplatin (3 mg/kg/day) was injected intraperitoneally into C57BL6J mice for five days with five days of rest for two cycles.
RESULTS: Mice in the Oxaliplatin-treated group exhibited significant mechanical anomalous pain. the Oxaliplatin group exhibited significant cold nociceptive hypersensitivity in the hindfoot. [5]
Kinase Assay
Binding experiments of electrophysiology: CHO cells expressing the subunit of the voltage-dependent L-type Ca2+ channel are cultrured in medium without serum in the presence of different concentrations of Nisoldipine. Then Ca2+ channel current elicited from a holding potential of -100 mV or -50 mV is recorded at room temperature with the whole-cell configuration of the patch-clamp method using the List EPC-7 patch-clamp amplifer and pClamp software. The concentration of competitor inhibiting 50% of the specific binding represents IC50.
Cell Research
The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control(Only for Reference)
AliasL-OHP
Chemical Properties
Molecular Weight397.29
FormulaC8H14N2O4Pt
Cas No.61825-94-3
SmilesO=C1O[Pt]OC1=O.N[C@@H]1CCCC[C@H]1N
Relative Density.no data available
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
Ethanol: < 1 mg/mL (insoluble)
DMSO: 50 mg/mL (125.85 mM), DMSO inactivates the activity of Oxaliplatin.
H2O: 2.5 mg/mL (6.29 mM), Sonication is recommended.
DMF: 1.67 mg/mL (4.20 mM), Sonication is recommended.
Solution Preparation Table
DMF/H2O/DMSO
1mg5mg10mg50mg
1 mM2.5171 mL12.5853 mL25.1705 mL125.8527 mL
H2O/DMSO
1mg5mg10mg50mg
5 mM0.5034 mL2.5171 mL5.0341 mL25.1705 mL
DMSO
1mg5mg10mg50mg
10 mM0.2517 mL1.2585 mL2.5171 mL12.5853 mL
20 mM0.1259 mL0.6293 mL1.2585 mL6.2926 mL
50 mM0.0503 mL0.2517 mL0.5034 mL2.5171 mL
100 mM0.0252 mL0.1259 mL0.2517 mL1.2585 mL

Sci Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Oxaliplatin | purchase Oxaliplatin | Oxaliplatin cost | order Oxaliplatin | Oxaliplatin chemical structure | Oxaliplatin in vivo | Oxaliplatin in vitro | Oxaliplatin formula | Oxaliplatin molecular weight